Vitamin B12 (cobalamin) is an essential water-soluble vitamin required for DNA synthesis, neurological function (myelin formation), and red blood cell maturation. It is unique among vitamins in requiring a complex absorption mechanism — dietary B12 must be released from food protein by gastric acid, then bound to intrinsic factor (produced by parietal cells in the stomach) before being absorbed in the terminal ileum via the cubilin receptor. Any disruption in this pathway — reduced gastric acid, intrinsic factor deficiency (pernicious anemia), terminal ileum disease (Crohn's), or drugs blocking the cubilin receptor (metformin) — produces functional B12 deficiency even with adequate dietary intake.
The neurological consequences of B12 deficiency are the most clinically serious aspect: subacute combined degeneration of the spinal cord (demyelination of the posterior and lateral columns) can produce irreversible neurological damage if deficiency is prolonged. Crucially, neurological symptoms often precede megaloblastic anemia — and folate supplementation (as in pregnancy) can correct the anemia while allowing neurological damage to continue undetected, making isolated B12 testing critical in high-folate environments.
| Form | Bioavailability | Notes | Best For |
|---|---|---|---|
| Cyanocobalamin | Excellent — the reference standard in clinical trials; requires conversion to methylcobalamin or adenosylcobalamin in cells; the "cyano" group is a small amount of cyanide (below toxicological significance at typical doses) that must be detoxified by the liver | Most stable form; used in most RCTs establishing B12 efficacy; cheapest; people with CKD (impaired cyanide clearance) should avoid high doses; MTHFR variant does not affect cyanocobalamin use | General supplementation; highest evidence base |
| Methylcobalamin | Equivalent to cyanocobalamin in correcting deficiency per head-to-head studies; bypasses one conversion step (already the active methyl donor form for methionine synthesis) | Less stable (light-sensitive); preferred by practitioners for MTHFR or methylation concerns; does not need liver conversion; more expensive; some evidence for longer tissue retention | Neurological applications; methylation support; pregnancy; patients with liver dysfunction |
| Adenosylcobalamin | The mitochondrial form — required for succinyl-CoA synthesis (energy metabolism); often combined with methylcobalamin in "complete B12" products | Less commonly studied independently; relevant for energy metabolism and MMA reduction (elevated MMA requires adenosylcobalamin, not methylcobalamin) | MMA elevation; energy metabolism; often combined with methylcobalamin |
| Hydroxocobalamin | Injectable form used in clinical deficiency treatment; longer half-life than cyanocobalamin injection; binds cyanide (used as antidote in cyanide poisoning) | Used in pernicious anemia and severe deficiency via injection; not a common oral supplement | Pernicious anemia (injection); cyanide poisoning antidote |
| Sublingual vs oral | Both effective for supplementation; at doses ≥1,000mcg, passive diffusion (independent of intrinsic factor) absorbs ~1% — sufficient to correct deficiency; sublingual claims superior absorption, but most RCTs show oral high-dose performs equally | Sublingual is preferred for pernicious anemia or severe malabsorption where even passive diffusion may be impaired; for general supplementation, swallowed tablets are equally effective | Pernicious anemia: sublingual or injection; general: either works |
The standard serum B12 test measures total cobalamin in blood — but much of circulating B12 is bound to haptocorrin (transcobalamin I), a storage protein that is metabolically inactive. Only the fraction bound to transcobalamin II (holotranscobalamin, holoTC) — representing 20–30% of total serum B12 — is available for cellular uptake. When serum B12 is in the grey zone (200–400 pg/mL), total B12 may appear "normal" while cellular B12 delivery is insufficient.
More sensitive functional markers: Methylmalonic acid (MMA) — elevated when adenosylcobalamin is insufficient for the methylmalonyl-CoA mutase reaction; MMA >270 nmol/L (serum) or >300 mcg/g creatinine (urine) indicates functional B12 deficiency, even with normal serum B12. Homocysteine — elevated when methylcobalamin is insufficient for methionine synthase; >15 mcmol/L is associated with B12 deficiency (also elevated in folate and B6 deficiency). HoloTC (active B12) — the most sensitive early marker; <35 pmol/L indicates depleted active B12 before serum total B12 falls. For high-risk patients (vegans, elderly, metformin users), MMA + holoTC is the most informative panel.
Vegans and strict vegetarians: 1,000–2,000mcg cyanocobalamin or methylcobalamin daily (sublingual preferred but not essential); or 2,500mcg weekly. At these doses, passive diffusion absorbs approximately 10–20mcg/day — more than adequate to meet the 2.4mcg/day RDA. Alternatively, B12-fortified foods (plant milk, nutritional yeast, fortified cereals) checked to ensure consistent adequate intake. Test serum B12 + MMA annually, particularly in the first 1–2 years of starting a vegan diet when stores are being depleted.
Adults over 60: 500–1,000mcg/day of crystalline B12 (tablets, not food-bound B12) — at these doses, passive absorption bypasses intrinsic factor dependence. The NIH Office of Dietary Supplements specifically recommends crystalline B12 for people over 50 because food-cobalamin malabsorption is common with age-related gastric atrophy. Annual serum B12 monitoring; consider MMA if serum is in grey zone.
Metformin users: ADA recommends periodic B12 monitoring in all patients on long-term metformin. If serum B12 is in the grey zone (<400 pg/mL), supplement with 1,000mcg/day oral crystalline B12. Some clinicians recommend universal B12 supplementation for all long-term metformin users rather than waiting for measured deficiency, particularly given the insidious neurological presentation.
PPI (proton pump inhibitor) users: Chronic PPI use reduces gastric acid, impairing B12 release from food protein. Consider 1,000mcg/day crystalline B12 supplementation if on PPIs long-term (>2 years). Monitor B12 annually.
Pernicious anemia (autoimmune intrinsic factor deficiency): Traditional treatment: B12 injection (hydroxocobalamin or cyanocobalamin) monthly; bypasses intrinsic factor entirely. Evidence supports high-dose oral cyanocobalamin (1,000–2,000mcg/day) as equivalent to monthly injections for most patients — passive diffusion at this dose is sufficient. Patient preference and compliance drive the choice between oral and injection in clinical practice.
Deficiency treatment (confirmed low B12): 1,000mcg/day for 1–3 months to replete stores, then maintenance dosing per risk group above. Neurological symptoms may take weeks to months to improve after B12 normalization; some improvement may be incomplete if deficiency was prolonged.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.